MedTrace Logo

An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients

NCT01573910 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 985

Last updated 2015-05-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate Moxifloxacin 0.5% relative to Ofloxacin 0.3% in the treatment of bacterial conjunctivitis in Chinese patients.

Conditions

  • Bacterial Conjunctivitis

Interventions

DRUG

Moxifloxacin ophthalmic solution, 0.5%

DRUG

Ofloxacin ophthalmic solution, 0.3%

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Helen Yu, Lead CSM · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01573910 on ClinicalTrials.gov